Výsledky vyhledávání - "de Roos JADM"

Akademický článek

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020.

Autor: Kooijman JJ; Oncolines B.V., Oss, Netherlands., van Riel WE; Oncolines B.V., Oss, Netherlands., Dylus J; Oncolines B.V., Oss, Netherlands., Prinsen MBW; Netherlands Translational Research Center B.V., Oss, Netherlands., Grobben Y; Oncolines B.V., Oss, Netherlands., de Bitter TJJ; Oncolines B.V., Oss, Netherlands., van Doornmalen AM; Oncolines B.V., Oss, Netherlands., Melis JJTM; Oncolines B.V., Oss, Netherlands., Uitdehaag JCM; Netherlands Translational Research Center B.V., Oss, Netherlands., Narumi Y; Carna Biosciences, Inc., Kobe, Japan., Kawase Y; Carna Biosciences, Inc., Kobe, Japan., de Roos JADM; Oncolines B.V., Oss, Netherlands., Willemsen-Seegers N; Oncolines B.V., Oss, Netherlands., Zaman GJR; Oncolines B.V., Oss, Netherlands.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Sep 14; Vol. 12, pp. 953013. Date of Electronic Publication: 2022 Sep 14 (Print Publication: 2022).

Zobrazit plný text záznamu

Akademický článek

Identification and evaluation of candidate COVID-19 critical genes and medicinal drugs related to plasma cells.

Autor: Liu, Zhe^1,2 (AUTHOR), Petinrin, Olutomilayo Olayemi² (AUTHOR), Chen, Nanjun² (AUTHOR), Toseef, Muhammad² (AUTHOR), Liu, Fang³ (AUTHOR), Zhu, Zhongxu⁴ (AUTHOR) zhuzhongxu@him.cas.cn, Qi, Furong¹ (AUTHOR) qifurong2012@gmail.com, Wong, Ka-Chun^2,5 (AUTHOR) kc.w@cityu.edu.hk

Publikováno v: BMC Infectious Diseases. 10/3/2024, Vol. 24 Issue 1, p1-28. 28p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017.

Autor: Uitdehaag JCM; Netherlands Translational Research Center B.V., Oss, the Netherlands., Kooijman JJ; Netherlands Translational Research Center B.V., Oss, the Netherlands., de Roos JADM; Netherlands Translational Research Center B.V., Oss, the Netherlands., Prinsen MBW; Netherlands Translational Research Center B.V., Oss, the Netherlands., Dylus J; Netherlands Translational Research Center B.V., Oss, the Netherlands., Willemsen-Seegers N; Netherlands Translational Research Center B.V., Oss, the Netherlands., Kawase Y; Carna Biosciences, Inc., Kobe, Japan., Sawa M; Carna Biosciences, Inc., Kobe, Japan., de Man J; Netherlands Translational Research Center B.V., Oss, the Netherlands., van Gerwen SJC; Netherlands Translational Research Center B.V., Oss, the Netherlands., Buijsman RC; Netherlands Translational Research Center B.V., Oss, the Netherlands., Zaman GJR; Netherlands Translational Research Center B.V., Oss, the Netherlands. guido.zaman@ntrc.nl.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Feb; Vol. 18 (2), pp. 470-481. Date of Electronic Publication: 2018 Oct 31.

Zobrazit plný text záznamu

Akademický článek

The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.

Autor: Abad, Etna¹ (AUTHOR), Sandoz, Jérémy¹ (AUTHOR), Romero, Gerard^1,2 (AUTHOR), Zadra, Ivan¹ (AUTHOR), Urgel-Solas, Julia^1,3 (AUTHOR), Borredat, Pablo¹ (AUTHOR), Kourtis, Savvas³ (AUTHOR), Ortet, Laura¹ (AUTHOR), Martínez, Carlos M.⁴ (AUTHOR), Weghorn, Donate³ (AUTHOR), Sdelci, Sara³ (AUTHOR), Janic, Ana¹ (AUTHOR) ana.janic@upf.edu

Publikováno v: Journal of Experimental & Clinical Cancer Research (17569966). 4/29/2024, Vol. 43 Issue 1, p1-25. 25p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers.

Autor: Zaman GJR; Netherlands Translational Research Center B.V., Oss, the Netherlands. guido.zaman@ntrc.nl., de Roos JADM; Netherlands Translational Research Center B.V., Oss, the Netherlands., Libouban MAA; Netherlands Translational Research Center B.V., Oss, the Netherlands., Prinsen MBW; Netherlands Translational Research Center B.V., Oss, the Netherlands., de Man J; Netherlands Translational Research Center B.V., Oss, the Netherlands., Buijsman RC; Netherlands Translational Research Center B.V., Oss, the Netherlands., Uitdehaag JCM; Netherlands Translational Research Center B.V., Oss, the Netherlands.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2017 Nov; Vol. 16 (11), pp. 2609-2617. Date of Electronic Publication: 2017 Jul 27.

Zobrazit plný text záznamu

Akademický článek

Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.

Autor: Uitdehaag JCM; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., de Man J; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., Willemsen-Seegers N; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., Prinsen MBW; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., Libouban MAA; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., Sterrenburg JG; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., de Wit JJP; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., de Vetter JRF; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., de Roos JADM; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., Buijsman RC; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands., Zaman GJR; Netherlands Translational Research Center B.V., Kloosterstraat 9, 5349AB Oss, The Netherlands. Electronic address: guido.zaman@ntrc.nl.

Publikováno v: Journal of molecular biology [J Mol Biol] 2017 Jul 07; Vol. 429 (14), pp. 2211-2230. Date of Electronic Publication: 2017 May 21.

Zobrazit plný text záznamu

Akademický článek

Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.

Autor: Libouban MAA; Netherlands Translational Research Center B.V., Oss, The Netherlands.; Netherlands Cancer Institute, Amsterdam, The Netherlands., de Roos JADM; Netherlands Translational Research Center B.V., Oss, The Netherlands., Uitdehaag JCM; Netherlands Translational Research Center B.V., Oss, The Netherlands., Willemsen-Seegers N; Netherlands Translational Research Center B.V., Oss, The Netherlands., Mainardi S; Netherlands Cancer Institute, Amsterdam, The Netherlands., Dylus J; Netherlands Translational Research Center B.V., Oss, The Netherlands., de Man J; Netherlands Translational Research Center B.V., Oss, The Netherlands., Tops B; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Meijerink JPP; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Storchová Z; University of Kaiserslautern, Kaiserslautern, Germany., Buijsman RC; Netherlands Translational Research Center B.V., Oss, The Netherlands., Medema RH; Netherlands Cancer Institute, Amsterdam, The Netherlands., Zaman GJR; Netherlands Translational Research Center B.V., Oss, The Netherlands.

Publikováno v: Oncotarget [Oncotarget] 2017 Jun 13; Vol. 8 (24), pp. 38309-38325.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání